Kyntra Bio, Inc. (LON:0IL8)

Market Cap	22.21M -44.0%
Revenue (ttm)	6.17M -36.7%
Net Income	160.43M
EPS	39.71
Shares Out	n/a
PE Ratio	0.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	759
Average Volume	285
Open	7.84
Previous Close	7.65
Day's Range	7.45 - 8.07
52-Week Range	5.97 - 24.25
Beta	0.77
RSI	37.03
Earnings Date	Feb 23, 2026

About Kyntra Bio

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1993
• Employees: 225
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IL8

Financial Performance

In 2024, Kyntra Bio's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Financial numbers in USD